Natalizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3545 publications

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.

Journal: Handbook of clinical neurology

Published: January 12, 2026

Cladribine for people with multiple sclerosis.

Cladribine for people with multiple sclerosis.

Journal: The Cochrane database of systematic reviews

Published: January 09, 2026

Corrigendum to "Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants" [European Journal of Pharmaceutical Sciences, 215 (2025), 107301].

Corrigendum to "Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants" [European Journal of Pharmaceutical Sciences, 215 (2025), 107301].

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: January 08, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Author response to letter to the editor.

Author response to letter to the editor.

Journal: Journal of the neurological sciences

Published: December 19, 2025

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study.

Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study.

Journal: medRxiv : the preprint server for health sciences

Published: December 18, 2025

Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".

Comment on "wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab".

Journal: Journal of the neurological sciences

Published: November 30, 2025

Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk.

Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk.

Journal: Journal of Crohn's & colitis

Published: November 29, 2025

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Knowledge Graph-Guided Identification of Multiple Sclerosis and Therapeutic Trend Analysis: Real-World Evidence from Two Large Healthcare Systems.

Journal: medRxiv : the preprint server for health sciences

Published: November 26, 2025

Towards practical management of the Marburg variant of multiple sclerosis.

Towards practical management of the Marburg variant of multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: November 09, 2025

Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study.

Real-world COVID-19 immunity in multiple sclerosis (CoVaR-MS): A longitudinal follow up study.

Journal: Multiple sclerosis and related disorders

Published: November 04, 2025

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis.

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis.

Journal: Cureus

Published: October 25, 2025

Showing 1-12 of 3,545

Last Updated: 02/24/2026